Who to call at Immunovant, Inc., and when
Fundz watches for the moments Immunovant, Inc. starts buying, and tells you who to reach.
- An alert the day Immunovant, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Immunovant, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Immunovant, Inc.. With Fundz connected, it knows.
Immunovant, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
www.immunovant.com2 executive changes at Immunovant in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.
The seat is still open. No replacement has been named 338 days after this filing.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Immunovant's Chief Medical Officer, Michael Geffner, M.D., M.B.A., departed effective November 21, 2025, as part of a restructuring of the R&D leadership under CEO Eric Venker. Dr. Geffner will consult for the Company through April 30, 2026, and the transition may affect R&D direction.
Key Takeaways
Dr. Geffner ceased serving as Chief Medical Officer effective November 21, 2025, as part of a restructuring of R&D leadership under CEO Eric Venker.
Under a Separation Agreement and General Release, Dr. Geffner receives severance per his January 9, 2024 employment agreement and includes a standard release of claims in favor of the Company.
3 more takeaways
Related Filings (4)
4 more filings from Immunovant, Inc. in the last 90 days
Filing Overview
What This Means
Immunovant, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.